Provided by Tiger Trade Technology Pte. Ltd.

Phathom Pharmaceuticals

10.87
-0.2400-2.16%
Volume:46.59K
Turnover:508.28K
Market Cap:856.54M
PE:-3.58
High:11.03
Open:10.89
Low:10.86
Close:11.11
52wk High:18.31
52wk Low:2.21
Shares:78.80M
Float Shares:57.57M
Volume Ratio:1.90
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0342
EPS(LYR):-3.0342
ROE:-3489.00%
ROA:-31.37%
PB:-1.95
PE(LYR):-3.58

Loading ...

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)

THOMSON REUTERS
·
Nov 04, 2025

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

GlobeNewswire
·
Nov 04, 2025

Phathom Pharmaceuticals Inc - Topline Results of Phase 2 Eoe Study Expected in 2027

THOMSON REUTERS
·
Nov 04, 2025

Phathom Pharmaceuticals to Present at Jefferies Global Healthcare Conference

Reuters
·
Nov 03, 2025

Phathom Pharmaceuticals’ Q3 Earnings: Strong Growth Amid Challenges

TIPRANKS
·
Nov 01, 2025

Stock Track | Phathom Pharmaceuticals Soars 8.41% on Strong Q3 Results and Analyst Upgrade

Stock Track
·
Oct 31, 2025

Stock Track | Phathom Pharmaceuticals Soars 8.41% on Strong Q3 Results and Analyst Upgrade

Stock Track
·
Oct 31, 2025

Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Results and Analyst Upgrade

Stock Track
·
Oct 31, 2025

Stock Track | Phathom Pharmaceuticals Soars 5.79% Pre-market on Strong Q3 Earnings and Analyst Upgrade

Stock Track
·
Oct 31, 2025

Phathom Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 31, 2025

Phathom Pharmaceuticals: Strong Q3 Performance and Promising Growth Drive Buy Rating

TIPRANKS
·
Oct 31, 2025

Stock Track | Phathom Pharmaceuticals Soars 10.50% Pre-Market on Strong Q3 Results and Raised Guidance

Stock Track
·
Oct 30, 2025

Stock Track | Phathom Pharmaceuticals Soars 10.50% on Strong Q3 Results and Raised 2025 Guidance

Stock Track
·
Oct 30, 2025

Craig-Hallum Sticks to Its Buy Rating for Phathom Pharmaceuticals (PHAT)

TIPRANKS
·
Oct 30, 2025

Stock Track | Phathom Pharmaceuticals Soars 6.43% Pre-market on Strong Q3 Results and Raised Guidance

Stock Track
·
Oct 30, 2025

Phathom Q3 revenue up 25%, beats estimates

Reuters
·
Oct 30, 2025

Phathom Pharmaceuticals Reports Q3 Net Revenue of $49.5 Million

Reuters
·
Oct 30, 2025

BRIEF-Phathom Pharmaceuticals Q3 Net Income USD -30 Million

Reuters
·
Oct 30, 2025

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS
·
Oct 30, 2025

Phathom Pharmaceuticals Inc - 2025 Revenue Guidance Updated to $170-$175 Mln

THOMSON REUTERS
·
Oct 30, 2025